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In trials with binary outcomes, assessed repeatedly at pre-specified times and where the subject is considered to
have experienced a failure at the first occurrence of the outcome, interim analyses are performed, generally, after
half or more of the subjects have completed follow-up. Depending on the duration of accrual relative to the length
of follow-up, this may be inefficient, since there is a possibility that the trial will have completed accrual prior to the
interim analysis. An alternative is to plan the interim analysis after subjects have completed follow-up to a time that
is less than the fixed full follow-up duration. Using simulations, we evaluated three methods to estimate the event
proportion for the interim analysis in terms of type I and II errors and the probability of early stopping. We
considered: 1) estimation of the event proportion based on subjects who have been followed for a pre-specified
time (less than the full follow-up duration) or who experienced the outcome; 2) estimation of the event proportion
based on data from all subjects that have been randomized by the time of the interim analysis; and 3) the
Kaplan-Meier approach to estimate the event proportion at the time of the interim analysis. Our results show that
all methods preserve and have comparable type I and II errors in certain scenarios. In these cases, we recommend
using the Kaplan-Meier method because it incorporates all the available data and has greater probability of early
stopping when the treatment effect exists.
Keywords: Interim analysis; Binary outcome; Power; Type I errorBackground
Interim analyses that permit early stopping of a ran-
domized controlled trial (RCT) for extremely positive
results or for futility are included in the design for eth-
ical and economic reasons. Strategies have been devel-
oped for interim analyses such that the overall type I
error of the entire trial is preserved at a fixed level
(Haybittle 1971; O'Brien and Fleming 1979; Peto et al.
1976; Pocock 1977).
Often, the primary outcome is whether or not a sub-
ject experienced an event over a fixed period of time
T. In some trials, the outcome is assessed repeatedly
at pre-specified times during follow-up, and the subject
is considered a failure if the event occurs at any time.* Correspondence: parpia@mcmaster.ca
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in any medium, provided the original work is pFor example, in a cardiovascular RCT investigating the
effect of an intervention for preventing post-thrombotic
syndrome, subjects can be assessed every 6 months for
up to 24 months using a disease-specific questionnaire
(Enden et al. 2012; Vedantham et al. 2013). A failure has
occurred if the questionnaire score exceeds a pre-specified
threshold. Another example would be a breast cancer
radiotherapy RCT where adverse cosmesis (i.e. a dichot-
omy), assessed at 1, 3 and 5 years post-randomization,
would be the primary safety outcome and the focus of
the interim analysis.
Interim analyses are generally performed after half or
more of the subjects have completed follow-up (Pedley
2011). Depending on the duration of accrual relative to
the length of follow-up, this strategy may be inefficient
because it is possible that accrual will have been com-
pleted and patients will have finished treatment prior ton Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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done earlier and a statistically significant effect was
found, the trial may be stopped, and all future subjects
would receive the experimental therapy.
In this situation, one alternative is to plan an interim
analysis after a smaller percentage of subjects have com-
pleted full follow-up. However, there is a low probability
of terminating the trial early when the interim analysis is
based on so little information, and, therefore, such an
analysis would unnecessarily spend alpha (Togo and
Iwasaki 2013). A second alternative is to plan the in-
terim analysis after half or more of the subjects have
completed a specified portion of the follow-up R, where
R < T, and T is the fixed full follow-up duration for each
subject.
Several researchers have studied methods that com-
bine data from subjects who have completed full follow-
up with those who have been followed for duration R in
situations where the outcome is reversible (Marschner
and Becker 2001; Sooriyarachchi et al. 2006; Whitehead
et al. 2008). In our research, however, the situation is dif-
ferent in that the outcome can be ascertained at any of the
pre-specified visits during follow-up and is irreversible.
In this paper, we consider 3 methods of estimating the
interim event proportion (risk) for each treatment group
in an RCT for an interim analysis: 1) estimated event
proportion based only on subjects who have been
followed for at least duration R or who had an outcome
event; 2) the event proportion based on data from sub-
jects that have been randomized by the time of the in-
terim analysis, and 3) the Kaplan-Meier approach to
estimate the event proportion. We investigate the effect
of each method on the type I and II errors and the prob-
ability of early stopping through computer simulation of
various trial scenarios.
Methods
Consider a trial designed to detect an absolute risk reduc-
tion (ARR) between the standard group (π0) and the ex-
perimental group (π1) over the time period 0 to T using a
normal approximation Z-test with
Z ¼ π^1−π^0ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
π^ 1 1−π^1ð Þ
n1
þ π^0 1−π^0ð Þn0
q
where π^0 and π^1 are the observed proportions, n0 and
n1 are the group sample sizes, and we are testing the
one-sided hypotheses H0: π1 ≥ π0 versus H1: π1 < π0. Fur-
thermore, we assume 90% power, an alpha of 0.025 and
a 1:1 randomization. Since the normal distribution is
symmetric, the p-value for a one-sided test is equivalent
to half of the two-sided p-value.
Suppose the trial requires 4 years for enrolment, each
subject is followed for 2 years (i.e. T = 24 months), andfailures are ascertained at any of the four 6-monthly pre-
specified visits post-randomization. Let the start of the
trial (calendar time) be denoted by τ0. Following the no-
tation in Table 1, let tj be the pre-specified visit times in
the trial where tj ≤ T and j is the visit number where j =
0, 1, 2… J, and J denotes the number of visits (e.g. J = 4
and t0 = 0, t1 = 6, t2 = 12, t3 = 18, t4 = 24 months). Sup-
pose an interim analysis is scheduled to occur when 50%
of the subjects have completed R = 12 months (t2 = R) of
follow-up which, assuming a uniform recruitment pat-
tern, corresponds to approximately 36 months after the
start of the trial, denoted by τ1 (Figure 1). At the interim
analysis, the proportion of subjects who fail in each
group could be estimated using any of the following
approaches.
Method 1: event proportion based on subjects followed
for at least duration R or who had an event
In RCTs where the length of enrolment relative to follow-
up is not an issue, subjects included in the interim analysis
are those who have completed their full follow-up T or
who have had an event prior to completion (Pedley 2011).
A similar approach is used here whereby we include only
subjects who have completed at least duration R (where
tr = R, r refers to the visit at which follow-up time equals
R) of their full follow-up T, or have had an event prior
to this point. Since the interim analysis occurs after 50%
of the subjects have completed at least follow-up of R,
this approach includes the first 50% of enrolled subjects
plus those subjects that have experienced an event but
have not completed follow-up of R. For each treatment
group i (0 = standard, 1 = experimental) at visit time tj,
let mij be the number of subjects at risk (i.e. have com-
pleted visit at tj without having an event), and let eij be
the number of new events diagnosed. Then the event
proportion in treatment group i at the time of interim
analysis τ1 is given by:








The individuals who have experienced an event but
have not completed duration R of follow-up are included
in the numerator and the denominator.
Method 2: event proportion based on data from subjects
that have been randomized by the time of the interim
analysis
This simple approach uses data from the subjects random-
ized by the time of the interim analysis τ1 (i.e. once 50% of
the subjects have been followed for at least time R). Let ni
Table 1 Notation table for estimation of event proportions
Visit number J Visit time tj Subjects at risk mj New events ej Incidence at visit j dj
0 t0 (<6 m) m0 e0 = 0 d0 = 0
1 t1 (6 m) m1 e1 d1 = e1/m1
2 t2 (12 m) m2 e2 d2 = e2/m2
3 t3 (18 m) m3 e3 d3 = e3/m3
4 t4 (24 m) m4 e4 d4 = e4/m4
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treatment group i. Then the event proportion for each
group at the time of interim analysis τ1 is given by





which is simply the total number of observed events
divided by the number of subjects randomized by
time τ1.
Method 3: Kaplan-Meier approach
This approach also uses all the data available at the time
of the interim analysis τ1 (i.e. once 50% of the subjects
have been followed for at least time R). For individuals
who have not completed follow-up time T (i.e. the full
fixed follow-up duration) and have not had the event,
they are simply right-censored at the latest time that
they were observed. Then the Kaplan-Meier (KM) esti-
mates can be calculated using all randomized subjectsFigure 1 Plot showing the follow-up time in months for 10 subjects a
subjects have completed 12 months of follow-up.and the event proportion in treatment group i at the
time of interim analysis τ1 is given by
π^ i τ1ð Þ ¼ 1−Si Tð Þ
where Si (T) is the KM survivor function estimate. Follow-
ing the notation in Table 1, this is equivalent to




We evaluated these methods in terms of overall type I
and II errors and the probability of early stopping of the
trial for a positive result at the interim. The interim ana-
lysis was performed using the Haybittle-Peto (Haybittle
1971; Peto et al. 1976) and O’Brien-Fleming (O'Brien
and Fleming 1979) monitoring boundaries for extreme
positive results. These boundaries are conservative and
require small p-values for early stopping of the trial.
Other less conservative boundaries such as the Pocock
approach were not evaluated (Freidlin and Korn 2009;
Pocock 2005).nd the proposed time for the interim analysis after 5 (50%)
Table 3 Summary of the event distribution probabilities
for the simulated scenarios
Scenario Event distribution probabilities by visit time
t1, t2, t3, t4
Standard group Experimental group
1 0.25, 0.25, 0.25. 0.25 same as standard
2 0.35, 0.30, 0.20, 0.15 same as standard
3 0.15, 0.20, 0.30, 0.35 same as standard
4 0.15, 0.20, 0.30, 0.35 0.35, 0.30, 0.20, 0.15
5 0.35, 0.30, 0.20, 0.15 0.15, 0.20, 0.30, 0.35
Parpia et al. SpringerPlus 2014, 3:323 Page 4 of 7
http://www.springerplus.com/content/3/1/323Simulation
We considered six RCTs similar to the trial described in
the Methods section (see Table 2). Data for the binary
endpoint were generated using the binomial distribution
under the null and alternative hypotheses.
For each subject with an event, the time at which the
event occurred was randomly assigned to reflect five
clinically-plausible scenarios (Table 3), using the following:
1) events were distributed equally across the four time-
points with probabilities (0.25, 0.25, 0.25, 0.25) for both
groups; 2) the majority of the events occurred in the first
two time-points with probabilities (0.35, 0.30, 0.20, 0.15)
for both groups; 3) the majority of the events occurred in
the last two time-points with probabilities (0.15, 0.20, 0.30,
0.35) for both groups; 4) the standard group follows distri-
bution (3) and the experimental group follows distribution
(2); and 5) the reverse of scenario (4). Entry times for
subjects over 48 months were randomly generated from
a uniform distribution, and the interim analysis was car-
ried out after 50% of the subjects completed R = 12 months
of follow-up. We carried out 10,000 replications for each
trial. Given that Z (x) and Z (y) are the interim and
final test statistics, respectively, the type I error rate,
PHo Z xð Þ > g or Z xð Þ≤g and Z yð Þ > f½ ð Þ , and the type II
error, PH1 Z xð Þ≤g and Z yð Þ≤fð Þ, were obtained from data
generated under the null and alternative hypotheses,
respectively, where g and f are the interim and final
critical values of the O’Brien-Fleming (g = 2.797, f = 1.977)
and Haybittle-Peto (g = 3.0, f = 1.967) monitoring boundar-
ies. The probability of early stopping, PH1 Z xð Þ > gð Þ, was
obtained under the alternative hypotheses. All analysis
was performed in R 2.15 (www.r-project.org).Results
The results of the type I error rates for the three methods
are shown graphically in Figure 2. The three methods have
comparable type I error rates across each of the trials and
event distribution scenarios. The methods in general have
nominal or close-to-nominal type I error rates when the
event distribution probabilities are equivalent betweenTable 2 Summary of six trials considered for simulation











0.30 0.25 0.05 3342
0.30 0.20 0.10 796
0.30 0.10 0.20 160
0.50 0.45 0.05 4182
0.50 0.40 0.10 1030
0.50 0.30 0.20 242treatment groups or when the experimental treatment
group events occurred earlier in the trial compared with
the standard group. However, under these same scenarios,
slightly greater-than-nominal type I error rates are seen in
the trials where (π0, π1) = (0.30, 0.10) and (π0, π1) = (0.50,
0.45), where the type I error rates are approximately 0.03.
For the scenario where the experimental group events oc-
curred later in the trial compared with the standard group,
the type I error was generally inflated for all methods.
The three methods also have comparable type II error
rates (Figure 3). In general, under all event distribution
scenarios and trials, the type II error rates are comparable
to the nominal value of 0.10 regardless of the interim ana-
lysis method or stopping boundary rule. Moreover, in the
scenario where the experimental group events occurred
later in the trial compared with the standard group, the
type II errors rates are much lower than the nominal value
for the trials with ARRs of 0.05 and 0.10.
Under the alternative hypothesis, methods 1 and 3 have
comparable probabilities for early stopping in scenarios
where the treatment groups have equivalent event distri-
butions probabilities over time, specifically in the trials
where π0 = 0.30 (Figure 4). Method 3 has a slightly greater
probability of early stopping than method 1 in the trials
where π0 = 0.50. Moreover, method 2 has the smallest
probability of early stopping in scenarios where the treat-
ment groups had equivalent event distributions probabil-
ities over time. On the other hand, all methods have
comparable probabilities of early stopping in the scenarios
where the treatment groups had contrasting event distri-
butions over time. The highest probabilities for early stop-
ping are seen in the trials where the experimental group
had a smaller proportion of events occur earlier in the trial
compared with the standard group, and the lowest prob-
abilities of early stopping are seen in the opposite scenario.
In general, the probability for early stopping is greater
using the O’Brien-Fleming boundaries compared with the
Haybittle-Peto monitoring boundaries.
Discussion
In RCTs with binary endpoints, interim analyses are gener-
ally conducted after a considerable percentage of subjects
Figure 2 Overall type I error rates for each trial by event distribution scenario.
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ations this approach is not optimal since the trial may
have completed accrual and all the subjects will have
been treated by that time. We evaluated three approaches
for an interim analysis when a considerable percentage of
subjects complete a follow-up time that is less than the
planned trial follow-up.Figure 3 Overall type II error rates for each trial by event distributionWe observed that the type I error rates were compar-
able for all three methods. For most trials simulated,
under the scenarios where the event distributions were
equivalent between treatment groups or the experimen-
tal group had events occur earlier than the standard
group, the type I error rates were close to the nominal
value. These results concur with those of Pedley (2011),scenario.
Figure 4 Probabilities for early stopping under the alternative hypothesis for each trial by event distribution scenario.
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considerable percentage of subjects had completed full
follow-up (using method 2) produced nominal type 1
error rates, albeit in the situation where events could be
measured at any time during follow-up and not just at
specific time points. However, we also observed that the
type I error rate increased with increasing absolute risk
reduction for trials with a standard group event propor-
tion of 0.3, thus resulting in slightly higher type I error
rates for the trial with ARR to 0.20. In addition, similar
slightly higher type I error rates were seen in the trial
with a standard group event proportion of 0.5 and the
ARR = 0.05. This is perhaps due to a combination of less
variability and a small sample size for the former, and a
large sample size and small ARR for the latter. There-
fore, trialists should be cautious of using either of these
methods under these situations.
While there were situations in which the type I errors
were slightly inflated with all methods, the methods
performed much better with regard to the type II errors
under all scenarios, suggesting that these methods will
not have a negative effect on the power to detect the hy-
pothesized difference between treatment groups provided
the difference exists. Under the scenarios where the ex-
perimental group had events occur later compared with
the standard group, the methods showed increased overall
power because the probability of early stopping was
greater in these scenarios. However, under these sce-
narios, the type I error rates are inflated.
The methods differed on the probability of early stopping
under the alternative hypothesis with method 2 havingthe lowest probability. This is because this approach in-
cludes data from all subjects that have been randomized
by the time of the interim analysis in the denominator
of the estimation of the event proportion even though a
subgroup of these patients would not have had any as-
sessment of the outcome since they would not have
reached their first time point for outcome assessment.
The consequence is the dilution of the interim treatment
effect leading to lower interim power. Method 3 also uses
all available data from randomized subjects at the time of
the interim analysis. However, it employs a conditional
probability approach which differentiates between those
subjects who have not yet had an assessment visit (i.e. cen-
sored) and who are at risk at each assessment visit, thus
yielding a greater probability of early stopping. Similarly,
since method 1 uses only a subset of randomized subjects
at the time of the interim analysis, the estimated interim
treatment effect is less diluted and, therefore, has greater
probability for early stopping than method 2. Conversely,
since it uses a smaller number of subjects compared with
method 3, the probability for early stopping is slightly
lower than method 3 in trials where the standard group
event proportion is 0.5, because the variability is greater
for proportions closer to 0.5. Furthermore, we observed
that the probabilities for early stopping are greater using
the O’Brien-Fleming boundary compared with the
Haybittle-Peto boundary since it is less conservative.
Although the largest probabilities of early stopping
under the alternative hypothesis and the smallest type II
errors were seen under the scenario where the experi-
mental group had events occurring later compared with
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and, therefore, none of the methods can be recommended
in this situation. Since there is a delay in occurrence of the
event in the experimental group, this may be perceived as
an effect of treatment. However, in situations where inves-
tigators are interested in the occurrence of an event over a
fixed time period, this scenario, although rare, would still
be considered under the null hypothesis.
Our study had some limitations. The generalizability of
our findings may be limited since we evaluated six trial
scenarios with particular event distributions over time. In
diseases where the event distributions over time differ
from the ones evaluated in this research, further simula-
tions would be required to evaluate these methods. Sec-
ondly, we evaluated trials with one interim analysis after
50% of the subjects completed 12 months of follow-up
using the O’Brien-Fleming or Haybittle-Peto approach.
These findings may not be applicable to trials in which in-
terim analyses are required at multiple times or when
using the alpha spending function approach to monitor
the trial. Finally, the biases of the interim event propor-
tions and treatment effects were not evaluated primarily
because it is well known that estimators at the interim are
biased, especially for estimators that allow for early stop-
ping for positive results. However, further investigation on
the estimators is needed.
Conclusion
Nonetheless, we have shown that under certain scenarios,
conducting an interim analysis when a considerable num-
ber of subjects have some follow-up data, using any of the
methods, preserves the type I and II errors. Although all
three methods preserve type I and II errors under these
scenarios, we recommend using the Kaplan-Meier method
because it incorporates all the available data and has
greater probability of early stopping when the treatment
effect exists. We have also shown that under certain sce-
narios, none of these methods is suitable for an interim
analysis, and trialists should be cautious when using them.
Finally, when possible, an interim analysis should be
undertaken when data from a considerable number of
subjects who have completed full follow-up are available.
However, if waiting for a considerable number of subjects
to complete full follow-up is not an efficient approach,
such as in the examples described, the methods outlines
in this paper should be considered and evaluated to fit the
specific needs of the trial.
Competing interests
The authors declare that they have no competing interests.
Author’s contributions
SP, JAJ, CG, LT and MNL conceived the study. SP conducted literature review,
designed and implemented the simulation, and wrote the initial draft of the
manuscript. All authors reviewed and revised the draft version of themanuscript. All authors read and approved the final version of the
manuscript.
Acknowledgements
This research was funded in part by funds from the CANNeCTIN Program.
Author details
1Ontario Clinical Oncology Group, Department of Oncology, McMaster
University, 711 Concession Street – G (60) Wing 1st Floor, Hamilton, ON L8V
1C3, Canada. 2Biostatistics Unit - FSORC, St Joseph’s Healthcare - Hamilton,
50 Charlton Avenue East, Hamilton, ON L8N 4A6, Canada.
Received: 2 April 2014 Accepted: 20 June 2014
Published: 26 June 2014
References
Enden T, Haig Y, Klow NE, Slagsvold CE, Sandvik L, Ghanima W, Hafsahl G, Holme
PA, Holmen LO, Njaastad AM, Sandbaek G, Sandset PM, CaVenT Study Group
(2012) Long-term outcome after additional catheter-directed thrombolysis
versus standard treatment for acute iliofemoral deep vein thrombosis
(the CaVenT study): a randomised controlled trial. Lancet 379(9810):31–38
Freidlin B, Korn EL (2009) Stopping clinical trials early for benefit: impact on
estimation. Clin Trials 6(2):119–125
Haybittle JL (1971) Repeated assessment of results in clinical trials of cancer
treatment. Br J Radiol 44(526):793–797
Marschner IC, Becker SL (2001) Interim monitoring of clinical trials based on
long-term binary endpoints. Stat Med 20(2):177–192
O'Brien P, Fleming T (1979) A multiple testing procedure for clinical trials.
Biometrics 35:549–556
Pedley A (2011) Applying survival analysis techniques to interim analysis and
sample size reassessment of clinical trials with dichotomous endpoint.
ProQuest, UMI Dissertations Publishing, Dissertation, Boston University
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N,
McPherson K, Peto J, Smith PG (1976) Design and analysis of randomized
clinical trials requiring prolonged observation of each patient. I. Introduction
and design. Br J Cancer 34(6):585–612
Pocock S (1977) Group sequential methods in the design and analysis of clinical
trials. Biometrika 64:191–199
Pocock SJ (2005) When (not) to stop a clinical trial for benefit. JAMA 294
(17):2228–2230
Sooriyarachchi MR, Whitehead J, Whitehead A, Bolland K (2006) The sequential
analysis of repeated binary responses: a score test for the case of three time
points. Stat Med 25(12):2196–2214
Togo K, Iwasaki M (2013) Optimal timing for interim analyses in clinical trials.
J Biopharm Stat 23(5):1067–1080
Vedantham S, Goldhaber SZ, Kahn SR, Julian J, Magnuson E, Jaff MR, Murphy TP,
Cohen DJ, Comerota AJ, Gornik HL, Razavi MK, Lewis L, Kearon C (2013)
Rationale and design of the ATTRACT Study: a multicenter randomized trial
to evaluate pharmacomechanical catheter-directed thrombolysis for the
prevention of postthrombotic syndrome in patients with proximal deep vein
thrombosis. Am Heart J 165(4):530, e3
Whitehead A, Sooriyarachchi MR, Whitehead J, Bolland K (2008) Incorporating
intermediate binary responses into interim analyses of clinical trials: a
comparison of four methods. Stat Med 27(10):1646–1666
doi:10.1186/2193-1801-3-323
Cite this article as: Parpia et al.: Interim analysis for binary outcome
trials with a long fixed follow-up time and repeated outcome
assessments at pre-specified times. SpringerPlus 2014 3:323.
